We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App

PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: The Vanadis NIPT screening platform demonstrated at AACC 2022 (Photo courtesy of PerkinElmer)
Image: The Vanadis NIPT screening platform demonstrated at AACC 2022 (Photo courtesy of PerkinElmer)

PerkinElmer, Inc. (Waltham, MA; USA) will be showcasing complete workflows for laboratories, including automation, instrumentation, and reagents, at the 2022 AACC Clinical Lab Expo.

The PerkinElmer exhibit booth will feature demonstrations of its high-throughput Vanadis NIPT solution that takes all the complexity out of noninvasive prenatal testing, making it accessible to more women – and more cost-effective for laboratories. This breakthrough cell-free DNA (cfDNA) technology eliminates PCR amplification and gene sequencing, making it so easy to use that one laboratory technician can handle 2000 to 20 000 samples per year. Walkaway automation streamlines the process from primary tube to final results. Because the Vanadis system is an easy to use, non-NGS and non-PCR based method, any laboratory can use it.

With Vanadis NIPT, laboratories can screen for the risk of trisomies 21, 18, 13, as well as fetal sex determination. By targeting thousands of chromosomal sequences, the Vanadis system can bring high precision non-invasive prenatal testing to labs, counting an average of 650,000 molecules per chromosome. With Vanadis technology, all the critical steps are automated, starting with pipetting steps to reduce manual errors. Plasma volumes are monitored by camera to avoid contamination by the buffy coat, and samples and reagents are barcoded for complete tracking throughout the workflow. PerkinElmer’s software guides labs through the process, with user-friendly touchscreens, enabling remote workflow management for ease of use. Easy to integrate, the software is designed for LIMS connectivity, reducing manual errors while simplifying data management.

Vanadis is the only NIPT screening platform to enable targeted cfDNA analysis without PCR, instead directly capturing target fragments and labeling them for counting. A proprietary nanofilter plate then captures labeled molecules for imaging, eliminating the need for data-intensive steps such as DNA sequencing, microarrays, and microfluidics.

Related Links:
PerkinElmer, Inc. 

Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
COL-R Assay
Isothermal Microfluidic Chip Analyzer
CapitalBio RTisochip
Gold Supplier
Microplate-Strip Washer
Wellwash Versa

Print article


Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more


view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.